<?xml version="1.0" encoding="UTF-8"?>
<p id="para390">234 (21%) of 1137 patients died in the lenalidomide group and 226 (27%) of 834 patients died in the observation group. Median overall survival was not reached (95% CI 66–not reached) with lenalidomide and not reached (61–not reached) with observation. 3-year overall survival was 78·6% (95% Cl 75·6–81·6) in the lenalidomide group and 75·8% (72·4–79·2) in the observation group, and 5-year overall survival was 61·3% (95% Cl 56·6–66·1) in the lenalidomide group and 56·6% (51·5–61·7) in the observation group. No difference was detected between lenalidomide and observation for overall survival (HR 0·87 [95% CI 0·73–1·05]; p=0·15; 
 <xref rid="fig2" ref-type="fig">figure 2B</xref>). The most common cause of death was tumour load (
 <xref rid="sec1" ref-type="sec">appendix p 25</xref>).
</p>
